Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.61 |
| ▸ | CDK2 | P24941 | 14/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.61 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.61 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | MGMT | P16455 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830293 | 0.92 | CDK1 (0.60) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL8618497 | 0.86 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL8537496 | 0.85 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL6925964 | 0.84 | CDK1 (0.43) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL12227596 | 0.83 | CDK1 (0.42) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL15199737 | 0.83 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL822023 | 0.82 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL22639807 | 0.80 | CDK1 (0.48) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL14958629 | 0.79 | CDK1 (0.42) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| Methylguanine SCHEMBL29968306 | 0.79 | CDK1 (0.41) | CDK1CCNB1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287418-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| EP-2576565-B1 | CARBANUCLEOSIDE SYNTHESIS AND NOVEL INTERMEDIATE COMPOUNDS USEFUL THEREIN | ALPHORA RES INC (CA) | 2017-08-02 | — | — | EP | disclosed |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| EP-2488522-B1 | NOVEL METHOD FOR PREPARING ENTECAVIR AND INTERMEDIATE USED THEREIN | HANMI SCIENCE CO LTD (KR) | 2017-02-15 | — | — | EP | disclosed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | disclosed |
| US-9309249-B2 | Entecavir synthesis method and intermediate compound thereof | Zhejiang Ausun Pharmaceutical Co., Ltd (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| US-8658792-B2 | Carbanucleoside synthesis and novel intermediate compounds useful therein | ALPHORA RESEARCH INC. | 2014-02-25 | — | — | US | disclosed |
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| WO-2010074534-A2 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | HANMI PHARM. CO., LTD. (KR) | 2010-07-01 | — | — | WO | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-7541460-B2 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7511139-B2 | Photodesilylation, oxidation, deportection, reaction with triisopropyl orthoformate in presence of acid catalyst, further reacting acetic anhydride and acetic acid, hydrolysis with HCl to form entecavir; aniviral agent; hepatitis b | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| CN-1027373-C | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | CN | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| CN-1051180-A | The nucleosides that is used for the treatment of | WELLCOME FOUND (GB) | 1991-05-08 | — | — | CN | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | CDK1 1270/4885CCNB1 2227/4885CDK2 952/4885 |
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | SAMHD1, TYMP, SORD | CDK1 192/4885CCNB1 351/4885CDK2 241/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | CDK1 1270/4885CCNB1 2227/4885CDK2 952/4885 |
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | TYMS, TPMT, TRDMT1 | CDK1 1706/4885CCNB1 2252/4885CDK2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.